Pharmacogenomic Testing May Curb Drug Interactions in MDD

Pharmacogenetic testing, which is used to classify how patients with major depressive disorder (MDD) metabolize medications, reduces adverse drug-gene interactions, new research shows. In a randomized clinical trial that included almost 2000 adults with MDD, patients in the pharmacogenomics-guided group were more likely to receive an antidepressant that had no drug-gene interaction than the patients … Read more